Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Near-infrared fluorescence labeled anti-TAG-72 monoclonal antibodies for tumor imaging in colorectal cancer xenograft mice.

Zou P, Xu S, Povoski SP, Wang A, Johnson MA, Martin EW Jr, Subramaniam V, Xu R, Sun D.

Mol Pharm. 2009 Mar-Apr;6(2):428-40. doi: 10.1021/mp9000052.

2.

Multimodality imaging: beyond PET/CT and SPECT/CT.

Cherry SR.

Semin Nucl Med. 2009 Sep;39(5):348-53. doi: 10.1053/j.semnuclmed.2009.03.001. Review.

3.

New developments in imaging and functional biomarker technology for the assessment and management of cancer patients.

Hall NC, Zhang J, Povoski SP, Martin EW, Knopp MV.

Expert Rev Med Devices. 2009 Jul;6(4):347-51. doi: 10.1586/erd.09.21. Review. No abstract available.

PMID:
19572788
4.

PET/CT for the staging and follow-up of patients with malignancies.

Poeppel TD, Krause BJ, Heusner TA, Boy C, Bockisch A, Antoch G.

Eur J Radiol. 2009 Jun;70(3):382-92. doi: 10.1016/j.ejrad.2009.03.051. Epub 2009 Apr 29. Review.

PMID:
19406595
5.

Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET.

Dunphy MP, Lewis JS.

J Nucl Med. 2009 May;50 Suppl 1:106S-21S. doi: 10.2967/jnumed.108.057281. Epub 2009 Apr 20. Review.

6.

Tailoring therapy in colorectal cancer by PET-CT.

Vriens D, de Geus-Oei LF, van der Graaf WT, Oyen WJ.

Q J Nucl Med Mol Imaging. 2009 Apr;53(2):224-44. Review.

7.

New PET tracers for evaluation of solid tumor response to therapy.

Larson SM, Schoder H.

Q J Nucl Med Mol Imaging. 2009 Apr;53(2):158-66. Review.

PMID:
19293764
8.

Radiopharmaceuticals for oncology drug development: a pharmaceutical industry perspective.

Murphy PS, Bergström M.

Curr Pharm Des. 2009;15(9):957-65. Review.

PMID:
19275660
9.

A comprehensive overview of radioguided surgery using gamma detection probe technology.

Povoski SP, Neff RL, Mojzisik CM, O'Malley DM, Hinkle GH, Hall NC, Murrey DA Jr, Knopp MV, Martin EW Jr.

World J Surg Oncol. 2009 Jan 27;7:11. doi: 10.1186/1477-7819-7-11. Review.

10.
11.

Multimodal imaging approaches: PET/CT and PET/MRI.

Pichler BJ, Judenhofer MS, Pfannenberg C.

Handb Exp Pharmacol. 2008;(185 Pt 1):109-32. doi: 10.1007/978-3-540-72718-7_6. Review.

PMID:
18626801
12.

PET imaging for response assessment in lymphoma: potential and limitations.

Schöder H, Moskowitz C.

Radiol Clin North Am. 2008 Mar;46(2):225-41, viii. doi: 10.1016/j.rcl.2008.04.002. Review.

PMID:
18619378
13.

Dual-modality imaging: combining anatomy and function.

Townsend DW.

J Nucl Med. 2008 Jun;49(6):938-55. doi: 10.2967/jnumed.108.051276. Epub 2008 May 15. Review.

14.

Multimodality imaging of structure and function.

Townsend DW.

Phys Med Biol. 2008 Feb 21;53(4):R1-R39. doi: 10.1088/0031-9155/53/4/R01. Epub 2008 Jan 28. Review.

PMID:
18263942
15.

Oncologic PET tracers beyond [(18)F]FDG and the novel quantitative approaches in PET imaging.

Kumar R, Dhanpathi H, Basu S, Rubello D, Fanti S, Alavi A.

Q J Nucl Med Mol Imaging. 2008 Mar;52(1):50-65. Review.

16.

FDG PET/CT for the detection and evaluation of breast diseases: usefulness and limitations.

Lim HS, Yoon W, Chung TW, Kim JK, Park JG, Kang HK, Bom HS, Yoon JH.

Radiographics. 2007 Oct;27 Suppl 1:S197-213. doi: 10.1148/rg.27si075507. Review.

PMID:
18180227
17.

Anesthesia condition for (18)F-FDG imaging of lung metastasis tumors using small animal PET.

Woo SK, Lee TS, Kim KM, Kim JY, Jung JH, Kang JH, Cheon GJ, Choi CW, Lim SM.

Nucl Med Biol. 2008 Jan;35(1):143-50.

PMID:
18158953
19.

FDG-PET/CT for cancer management.

Otsuka H, Morita N, Yamashita K, Nishitani H.

J Med Invest. 2007 Aug;54(3-4):195-9. Review.

20.

Radioimmunoguided surgery (RIGS), PET/CT image-guided surgery, and fluorescence image-guided surgery: past, present, and future.

Sun D, Bloomston M, Hinkle G, Al-Saif OH, Hall NC, Povoski SP, Arnold MW, Martin EW Jr.

J Surg Oncol. 2007 Sep 15;96(4):297-308.

PMID:
17726663

Supplemental Content

Support Center